Global Recombinant Protein Drugs Market Report, History and Forecast 2017-2028, Breakdown Data by Manufacturers, Key Regions, Types and Application
Report Code: KNJ1408871 No. of Pages: 110 Category: Medical Devices
Publisher: Date of Publish:
Publisher: Date of Publish:
Market Overview Due to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Recombinant Protein Drugs estimated at US$ million in the year 2022, is projected to reach a revised size of US$ million by 2028, growing at a CAGR of % during the forecast period 2022-2028. North American market for Recombinant Protein Drugs is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028. Asia-Pacific market for Recombinant Protein Drugs is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2022 through 2028. Europe market for Recombinant Protein Drugs is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2022 through 2028. Report Scope This report aims to provide a comprehensive presentation of the global market for Recombinant Protein Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Recombinant Protein Drugs. The Recombinant Protein Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Doses) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Recombinant Protein Drugs market comprehensively. Regional market sizes, concerning products by types, by application, and by players, are also provided. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Recombinant Protein Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market. Market Segmentation This report covers the Recombinant Protein Drugs segments by manufacturers, by type, by application, by region and country, and provides market size (value, volume and average price) and CAGR for the history and forecast period (2017-2022, 2023-2028), considering 2021 as the base year. It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market. By Company Novo Nordisk Amgen Sanofi Eli Lilly Merck Serono Ortho Biotech Roche Kyowa Hakko Kirin Pharmingen Abcam GenSci SL PHARM Dongbao Pharm Ankebio NCPC Heng Rui Recombinant Protein Drugs Segment by Type Recombinant DNA Recombinant RNA Recombinant Protein Drugs Segment by Application Pharmaceutical Industry Others Recombinant Protein Drugs Segment by Region North America (USA and Canada) Europe (Germany, the U.K., France, Russia, Italy, Rest of Europe) Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific) South America (Mexico, Brazil, Rest of South America) Middle East and Africa (Saudi Arabia, UAE, Egypt, South Africa, Rest of MEA) Key Drivers & Barriers High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects. COVID-19 and Russia-Ukraine War Influence Analysis The readers in the section will understand how the Recombinant Protein Drugs market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come. Reasons to Buy This Report Informative and detailed data, sales, revenue, average price, historical and forecast data, which is analyzed to tell you why your market is set to change. Provision of market value (USD million) data for each segment and sub-segment. This report will help stakeholders to understand the global industry status and trends of Recombinant Protein Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities. This enables you to anticipate market changes to remain ahead of your competitors. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition. This concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly. This report helps stakeholders to understand the COVID-19 and Russia-Ukraine War Influence on the Recombinant Protein Drugs industry. Keeping in mind the uncertainties of COVID-19 and Russia-Ukraine War, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor. Core Chapters Chapter One: Introduces the study scope of this report, executive summary of market segments by type, market size by type for North America, Europe, Asia Pacific, Latin America, Middle East & Africa. Chapter Two: Detailed analysis of Recombinant Protein Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc. Chapter Three: Sales, revenue of Recombinant Protein Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world. Chapter Four: Introduces market segments by application, market size by application for North America, Europe, Asia Pacific, Latin America, Middle East & Africa. Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, sales and revenue by country. Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc. Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry. Chapter Twelve: Research Findings and Conclusion
1 Recombinant Protein Drugs Market Overview 1.1 Recombinant Protein Drugs Product Overview 1.2 Recombinant Protein Drugs Market Segment by Type 1.2.1 Recombinant DNA 1.2.2 Recombinant RNA 1.3 Global Recombinant Protein Drugs Market Size by Type 1.3.1 Global Recombinant Protein Drugs Market Size Overview by Type (2017-2028) 1.3.2 Global Recombinant Protein Drugs Historic Market Size Review by Type (2017-2022) 1.3.2.1 Global Recombinant Protein Drugs Sales Breakdown in Volume by Type (2017-2022) 1.3.2.2 Global Recombinant Protein Drugs Sales Breakdown in Value by Type (2017-2022) 1.3.2.3 Global Recombinant Protein Drugs Average Selling Price (ASP) by Type (2017-2022) 1.3.3 Global Recombinant Protein Drugs Forecasted Market Size by Type (2023-2028) 1.3.3.1 Global Recombinant Protein Drugs Sales Breakdown in Volume by Type (2023-2028) 1.3.3.2 Global Recombinant Protein Drugs Sales Breakdown in Value by Type (2023-2028) 1.3.3.3 Global Recombinant Protein Drugs Average Selling Price (ASP) by Type (2023-2028) 1.4 Key Regions Market Size Segment by Type 1.4.1 North America Recombinant Protein Drugs Sales Breakdown by Type (2017-2022) 1.4.2 Europe Recombinant Protein Drugs Sales Breakdown by Type (2017-2022) 1.4.3 Asia-Pacific Recombinant Protein Drugs Sales Breakdown by Type (2017-2022) 1.4.4 Latin America Recombinant Protein Drugs Sales Breakdown by Type (2017-2022) 1.4.5 Middle East and Africa Recombinant Protein Drugs Sales Breakdown by Type (2017-2022) 2 Global Recombinant Protein Drugs Market Competition by Company 2.1 Global Top Players by Recombinant Protein Drugs Sales (2017-2022) 2.2 Global Top Players by Recombinant Protein Drugs Revenue (2017-2022) 2.3 Global Top Players Recombinant Protein Drugs Price (2017-2022) 2.4 Global Top Manufacturers Recombinant Protein Drugs Manufacturing Base Distribution, Sales Area, Product Type 2.5 Recombinant Protein Drugs Market Competitive Situation and Trends 2.5.1 Recombinant Protein Drugs Market Concentration Rate (2017-2022) 2.5.2 Global 5 and 10 Largest Manufacturers by Recombinant Protein Drugs Sales and Revenue in 2021 2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Recombinant Protein Drugs as of 2021) 2.7 Date of Key Manufacturers Enter into Recombinant Protein Drugs Market 2.8 Key Manufacturers Recombinant Protein Drugs Product Offered 2.9 Mergers & Acquisitions, Expansion 3 Recombinant Protein Drugs Status and Outlook by Region 3.1 Global Recombinant Protein Drugs Market Size and CAGR by Region: 2017 VS 2021 VS 2028 3.2 Global Recombinant Protein Drugs Historic Market Size by Region 3.2.1 Global Recombinant Protein Drugs Sales in Volume by Region (2017-2022) 3.2.2 Global Recombinant Protein Drugs Sales in Value by Region (2017-2022) 3.2.3 Global Recombinant Protein Drugs Sales (Volume & Value) Price and Gross Margin (2017-2022) 3.3 Global Recombinant Protein Drugs Forecasted Market Size by Region 3.3.1 Global Recombinant Protein Drugs Sales in Volume by Region (2023-2028) 3.3.2 Global Recombinant Protein Drugs Sales in Value by Region (2023-2028) 3.3.3 Global Recombinant Protein Drugs Sales (Volume & Value), Price and Gross Margin (2023-2028) 4 Global Recombinant Protein Drugs by Application 4.1 Recombinant Protein Drugs Market Segment by Application 4.1.1 Pharmaceutical Industry 4.1.2 Others 4.2 Global Recombinant Protein Drugs Market Size by Application 4.2.1 Global Recombinant Protein Drugs Market Size Overview by Application (2017-2028) 4.2.2 Global Recombinant Protein Drugs Historic Market Size Review by Application (2017-2022) 4.2.2.1 Global Recombinant Protein Drugs Sales Breakdown in Volume, by Application (2017-2022) 4.2.2.2 Global Recombinant Protein Drugs Sales Breakdown in Value, by Application (2017-2022) 4.2.2.3 Global Recombinant Protein Drugs Average Selling Price (ASP) by Application (2017-2022) 4.2.3 Global Recombinant Protein Drugs Forecasted Market Size by Application (2023-2028) 4.2.3.1 Global Recombinant Protein Drugs Sales Breakdown in Volume, by Application (2023-2028) 4.2.3.2 Global Recombinant Protein Drugs Sales Breakdown in Value, by Application (2023-2028) 4.2.3.3 Global Recombinant Protein Drugs Average Selling Price (ASP) by Application (2023-2028) 4.3 Key Regions Market Size Segment by Application 4.3.1 North America Recombinant Protein Drugs Sales Breakdown by Application (2017-2022) 4.3.2 Europe Recombinant Protein Drugs Sales Breakdown by Application (2017-2022) 4.3.3 Asia-Pacific Recombinant Protein Drugs Sales Breakdown by Application (2017-2022) 4.3.4 Latin America Recombinant Protein Drugs Sales Breakdown by Application (2017-2022) 4.3.5 Middle East and Africa Recombinant Protein Drugs Sales Breakdown by Application (2017-2022) 5 North America Recombinant Protein Drugs by Country 5.1 North America Recombinant Protein Drugs Historic Market Size by Country 5.1.1 North America Recombinant Protein Drugs Sales in Volume by Country (2017-2022) 5.1.2 North America Recombinant Protein Drugs Sales in Value by Country (2017-2022) 5.2 North America Recombinant Protein Drugs Forecasted Market Size by Country 5.2.1 North America Recombinant Protein Drugs Sales in Volume by Country (2023-2028) 5.2.2 North America Recombinant Protein Drugs Sales in Value by Country (2023-2028) 6 Europe Recombinant Protein Drugs by Country 6.1 Europe Recombinant Protein Drugs Historic Market Size by Country 6.1.1 Europe Recombinant Protein Drugs Sales in Volume by Country (2017-2022) 6.1.2 Europe Recombinant Protein Drugs Sales in Value by Country (2017-2022) 6.2 Europe Recombinant Protein Drugs Forecasted Market Size by Country 6.2.1 Europe Recombinant Protein Drugs Sales in Volume by Country (2023-2028) 6.2.2 Europe Recombinant Protein Drugs Sales in Value by Country (2023-2028) 7 Asia-Pacific Recombinant Protein Drugs by Region 7.1 Asia-Pacific Recombinant Protein Drugs Historic Market Size by Region 7.1.1 Asia-Pacific Recombinant Protein Drugs Sales in Volume by Region (2017-2022) 7.1.2 Asia-Pacific Recombinant Protein Drugs Sales in Value by Region (2017-2022) 7.2 Asia-Pacific Recombinant Protein Drugs Forecasted Market Size by Region 7.2.1 Asia-Pacific Recombinant Protein Drugs Sales in Volume by Region (2023-2028) 7.2.2 Asia-Pacific Recombinant Protein Drugs Sales in Value by Region (2023-2028) 8 Latin America Recombinant Protein Drugs by Country 8.1 Latin America Recombinant Protein Drugs Historic Market Size by Country 8.1.1 Latin America Recombinant Protein Drugs Sales in Volume by Country (2017-2022) 8.1.2 Latin America Recombinant Protein Drugs Sales in Value by Country (2017-2022) 8.2 Latin America Recombinant Protein Drugs Forecasted Market Size by Country 8.2.1 Latin America Recombinant Protein Drugs Sales in Volume by Country (2023-2028) 8.2.2 Latin America Recombinant Protein Drugs Sales in Value by Country (2023-2028) 9 Middle East and Africa Recombinant Protein Drugs by Country 9.1 Middle East and Africa Recombinant Protein Drugs Historic Market Size by Country 9.1.1 Middle East and Africa Recombinant Protein Drugs Sales in Volume by Country (2017-2022) 9.1.2 Middle East and Africa Recombinant Protein Drugs Sales in Value by Country (2017-2022) 9.2 Middle East and Africa Recombinant Protein Drugs Forecasted Market Size by Country 9.2.1 Middle East and Africa Recombinant Protein Drugs Sales in Volume by Country (2023-2028) 9.2.2 Middle East and Africa Recombinant Protein Drugs Sales in Value by Country (2023-2028) 10 Company Profiles and Key Figures in Recombinant Protein Drugs Business 10.1 Novo Nordisk 10.1.1 Novo Nordisk Corporation Information 10.1.2 Novo Nordisk Introduction and Business Overview 10.1.3 Novo Nordisk Recombinant Protein Drugs Sales, Revenue and Gross Margin (2017-2022) 10.1.4 Novo Nordisk Recombinant Protein Drugs Products Offered 10.1.5 Novo Nordisk Recent Development 10.2 Amgen 10.2.1 Amgen Corporation Information 10.2.2 Amgen Introduction and Business Overview 10.2.3 Amgen Recombinant Protein Drugs Sales, Revenue and Gross Margin (2017-2022) 10.2.4 Amgen Recombinant Protein Drugs Products Offered 10.2.5 Amgen Recent Development 10.3 Sanofi 10.3.1 Sanofi Corporation Information 10.3.2 Sanofi Introduction and Business Overview 10.3.3 Sanofi Recombinant Protein Drugs Sales, Revenue and Gross Margin (2017-2022) 10.3.4 Sanofi Recombinant Protein Drugs Products Offered 10.3.5 Sanofi Recent Development 10.4 Eli Lilly 10.4.1 Eli Lilly Corporation Information 10.4.2 Eli Lilly Introduction and Business Overview 10.4.3 Eli Lilly Recombinant Protein Drugs Sales, Revenue and Gross Margin (2017-2022) 10.4.4 Eli Lilly Recombinant Protein Drugs Products Offered 10.4.5 Eli Lilly Recent Development 10.5 Merck Serono 10.5.1 Merck Serono Corporation Information 10.5.2 Merck Serono Introduction and Business Overview 10.5.3 Merck Serono Recombinant Protein Drugs Sales, Revenue and Gross Margin (2017-2022) 10.5.4 Merck Serono Recombinant Protein Drugs Products Offered 10.5.5 Merck Serono Recent Development 10.6 Ortho Biotech 10.6.1 Ortho Biotech Corporation Information 10.6.2 Ortho Biotech Introduction and Business Overview 10.6.3 Ortho Biotech Recombinant Protein Drugs Sales, Revenue and Gross Margin (2017-2022) 10.6.4 Ortho Biotech Recombinant Protein Drugs Products Offered 10.6.5 Ortho Biotech Recent Development 10.7 Roche 10.7.1 Roche Corporation Information 10.7.2 Roche Introduction and Business Overview 10.7.3 Roche Recombinant Protein Drugs Sales, Revenue and Gross Margin (2017-2022) 10.7.4 Roche Recombinant Protein Drugs Products Offered 10.7.5 Roche Recent Development 10.8 Kyowa Hakko Kirin 10.8.1 Kyowa Hakko Kirin Corporation Information 10.8.2 Kyowa Hakko Kirin Introduction and Business Overview 10.8.3 Kyowa Hakko Kirin Recombinant Protein Drugs Sales, Revenue and Gross Margin (2017-2022) 10.8.4 Kyowa Hakko Kirin Recombinant Protein Drugs Products Offered 10.8.5 Kyowa Hakko Kirin Recent Development 10.9 Pharmingen 10.9.1 Pharmingen Corporation Information 10.9.2 Pharmingen Introduction and Business Overview 10.9.3 Pharmingen Recombinant Protein Drugs Sales, Revenue and Gross Margin (2017-2022) 10.9.4 Pharmingen Recombinant Protein Drugs Products Offered 10.9.5 Pharmingen Recent Development 10.10 Abcam 10.10.1 Abcam Corporation Information 10.10.2 Abcam Introduction and Business Overview 10.10.3 Abcam Recombinant Protein Drugs Sales, Revenue and Gross Margin (2017-2022) 10.10.4 Abcam Recombinant Protein Drugs Products Offered 10.10.5 Abcam Recent Development 10.11 GenSci 10.11.1 GenSci Corporation Information 10.11.2 GenSci Introduction and Business Overview 10.11.3 GenSci Recombinant Protein Drugs Sales, Revenue and Gross Margin (2017-2022) 10.11.4 GenSci Recombinant Protein Drugs Products Offered 10.11.5 GenSci Recent Development 10.12 SL PHARM 10.12.1 SL PHARM Corporation Information 10.12.2 SL PHARM Introduction and Business Overview 10.12.3 SL PHARM Recombinant Protein Drugs Sales, Revenue and Gross Margin (2017-2022) 10.12.4 SL PHARM Recombinant Protein Drugs Products Offered 10.12.5 SL PHARM Recent Development 10.13 Dongbao Pharm 10.13.1 Dongbao Pharm Corporation Information 10.13.2 Dongbao Pharm Introduction and Business Overview 10.13.3 Dongbao Pharm Recombinant Protein Drugs Sales, Revenue and Gross Margin (2017-2022) 10.13.4 Dongbao Pharm Recombinant Protein Drugs Products Offered 10.13.5 Dongbao Pharm Recent Development 10.14 Ankebio 10.14.1 Ankebio Corporation Information 10.14.2 Ankebio Introduction and Business Overview 10.14.3 Ankebio Recombinant Protein Drugs Sales, Revenue and Gross Margin (2017-2022) 10.14.4 Ankebio Recombinant Protein Drugs Products Offered 10.14.5 Ankebio Recent Development 10.15 NCPC 10.15.1 NCPC Corporation Information 10.15.2 NCPC Introduction and Business Overview 10.15.3 NCPC Recombinant Protein Drugs Sales, Revenue and Gross Margin (2017-2022) 10.15.4 NCPC Recombinant Protein Drugs Products Offered 10.15.5 NCPC Recent Development 10.16 Heng Rui 10.16.1 Heng Rui Corporation Information 10.16.2 Heng Rui Introduction and Business Overview 10.16.3 Heng Rui Recombinant Protein Drugs Sales, Revenue and Gross Margin (2017-2022) 10.16.4 Heng Rui Recombinant Protein Drugs Products Offered 10.16.5 Heng Rui Recent Development 11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis 11.1 Recombinant Protein Drugs Key Raw Materials 11.1.1 Key Raw Materials 11.1.2 Key Raw Materials Price 11.1.3 Raw Materials Key Suppliers 11.2 Manufacturing Cost Structure 11.2.1 Raw Materials 11.2.2 Labor Cost 11.2.3 Manufacturing Expenses 11.3 Recombinant Protein Drugs Industrial Chain Analysis 11.4 Recombinant Protein Drugs Market Dynamics 11.4.1 Recombinant Protein Drugs Industry Trends 11.4.2 Recombinant Protein Drugs Market Drivers 11.4.3 Recombinant Protein Drugs Market Challenges 11.4.4 Recombinant Protein Drugs Market Restraints 12 Market Strategy Analysis, Distributors 12.1 Sales Channel 12.2 Recombinant Protein Drugs Distributors 12.3 Recombinant Protein Drugs Downstream Customers 13 Research Findings and Conclusion 14 Appendix 14.1 Research Methodology 14.1.1 Methodology/Research Approach 14.1.1.1 Research Programs/Design 14.1.1.2 Market Size Estimation 14.1.1.3 Market Breakdown and Data Triangulation 14.1.2 Data Source 14.1.2.1 Secondary Sources 14.1.2.2 Primary Sources 14.2 Author Details 14.3 Disclaimer
NEED Help?
If you need any help or guidance, please feel free to call us.
USA : +1 (661) 636 6162
INDIA : +91 9325802062
or
Write us on : sales@kandjmarketresearch.com